WARREN, N.J., Nov. 19, 2024 (GLOBE NEWSWIRE) — Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, has announced financial results for the fiscal quarter ending September 30, 2024, and filed its quarterly report on Form 10-Q with the Securities and Exchange Commission.
GlobeNewswire,is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Latest posts by GlobeNewswire (see all)
- PST Group AB signed a EUR 42 million contract with UAB JPresswood for the construction of a complex of industrial buildings in Marijampolė - May 22, 2025
- Sunlands Technology Group Announces Unaudited First Quarter 2025 Financial Results - May 22, 2025
- Fast Payout Online Casinos: JACKBIT Voted #1 for Fast & Instant Withdrawals - May 22, 2025
